Notice

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Do you have Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)?

Credit: iStock
If you are being treated for SSc-PAH, you may be eligible for a clinical trial. The National Institute of Allergy and Infectious Diseases (NIAID) is seeking SSc-PAH patients to enroll in a treatment study being conducted to target the immune system, now thought to be a factor in this disease.

Current Treatments

Treatment is currently based on opening the small blood vessels in the lungs to ease the heart’s work of pumping blood to the lungs.

What’s New in Research?

B cells are immune cells that are thought to attack normal lung cells and that may lead to SSc-PAH. Rituximab eliminates B cells for a few months and is an FDA-approved immunosuppressive drug to treat other diseases. This clinical trial is researching if Rituximab treatment affects your SSc-PAH.

Who is Eligible for This Study?

If you are currently being treated with medications for PAH and are 18-75 years old, you may be eligible to participate in this clinical trial! You can learn more about ASC01 study (trial ID NCT01086540) by visiting clinicaltrials.gov

Content last reviewed on December 28, 2016